key: cord-0871411-iwix5d0z
authors: Soltani, Saber; Faramarzi, Samireh; Zandi, Milad; Shahbahrami, Ramin; Jafarpour, Ali; Rezayat, Sara Akhavan; Pakzad, Iraj; Abdi, Fatemeh; Malekifar, Pooneh; Pakzad, Reza
title: Bacterial Co-infection among COVID-19 patient groups: an update Systematic review and Meta-analysis
date: 2021-07-01
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2021.100910
sha: 75b3282eaefff9a47e5822576588d6a73e16a746
doc_id: 871411
cord_uid: iwix5d0z

Background The pandemic of SARS COV-2 raised the attention toward bacterial coinfection and their role in COVID-19 disease. This study aims to systematically review and identify the pooled prevalence of the bacterial coinfection in the related articles. Methods A comprehensive search was conducted in international databases, including Medline, Scopus, Web of Science, and Embase, to identify the articles on the prevalence of Bacterial coinfections in COIVD-19 patients from December 1, 2019, until December 30, 2020. All observational epidemiological studies that evaluated the prevalence of bacterial coinfections in COVID-19 patients included without any restriction. Results Forty two studies including total sample size of 54695 were included in the analysis. The pooled estimate for prevalence of bacterial coinfections was 20.97% (95% CI: 15.95 to 26.46) the pooled prevalence of bacterial coinfections was 5.20% (95% CI: 2.39 to 8.91) for Respiratory subtype and 4.79% (95% CI: 0.11 to 14.61) for Gastrointestinal subtype. The pooled prevalence for Eastern Mediterranean Regional Office (EMRO) and South-East Asia Regional Office (SEARO) was 100 % (95% CI: 82.35 to 100.00) and 2.61 % (95% CI: 1.74 to 3.62). Conclusion This rate of coinfection poses a great danger toward patients especially those in critical condition. Although there are multiple complication and adverse effect related to extensive use of antibiotics to treat COVID-19 patients but it seems there is no other option except the applying them and it needs to be done carefully.

• Saber Soltani: contributing in Study design, creation of models, Management activities to annotate (produce metadata), specifically writing the initial draft (including substantive translation) • Samireh Faramarzi: contributing in Data collection and writing the manuscript, developed the theory and performed the computations, specifically writing the initial draft (including substantive translation) 

Bacterial coinfection played an important role in escalating the morbidity and mortality rate during pervious viral outbreaks and pandemics [1] . The majority of patient's death during 1918-9 influenza pandemic were related to bacterial co pathogens rather than the virus itself [2] .

During H1N1pundemics several studies recorded the high prevalence of secondary and bacterial coinfection [3] . It also were reported people with bacterial coinfection showed high number of mortality among. Critical ill patients showed greater percentage of coinfection compare to hospitalized patients [4] . Previous experience during other respiratory viral infection supported the use of antibiotic so at the onset of COVID-19 infection early guideline for COVID-19 treatment suggested the use of antibiotics in all of the patients [5, 6] . Identification of prevalence of bacterial coinfection is crucial for the initial empiric antibiotic treatment, in SARS-COV2 patients. Different possible complication could occur because of extensive of implication of antibiotics in patients. Antibacterial resistance is one of the challenges due to this amount of

All observational epidemiological studies, including cohort, cross-sectional, and case series studies around the world that examined the prevalence of Bacterial coinfections in COVID-19 patients included without any restriction. Case reports and case series with a lesser than 10 sample sizes were excluded. Also, editorials, commentaries, case control, randomized clinical trial and reviews were excluded.

In addition to general information, including the name of authors, year, country, study design, sample size or number of COVID-19 patients, age, and sex, other data including number and type of Bacterial coinfections were extracted in all studies. Herein, the COVID-19 patients (confirmed cases based on molecular test such as polymerase chain reaction (PCR)) with even a single Bacterial coinfections were considered in the study.

Bacteria type were classified based on transmission way and clinical signs. Countries were categorized based on the latest WHO definition that includes the following six regions: Regional Office for Africa (AFRO), Regional Office of Americas (AMRO), and Regional Office for the Eastern Mediterranean (EMRO), Regional Office for Europe (EURO), Regional Office for South-East Asia (SEARO), and the Regional Office for the Western Pacific (WPRO).

The Newcastle-Ottawa Scale for case reports/case series and observational study was used to assess the quality of the included studies [11] . This scale has three sections: 1-selection (4 items, maximum score: 4 points), 2-Confounder (1 item, maximum score: 1 point), and 3-Exposure (2 items, maximum score: 2 points). The studies were evaluated by two raters (Reza Pakzad and J o u r n a l P r e -p r o o f Saber Soltani) independently, and a total score was calculated for each study. The studies were then assigned to one of the following categories accordingly: very good studies: 6-7 scores; good studies: 4-5 scores; satisfactory studies: 2-3 scores; unsatisfactory studies: 0-1 score [12] .

All analysis was conducted with Stata software 14.0 (college station, Texas). As previous studies [13] [14] [15] [16] , the number of COVID-19 cases, the prevalence of bacterial coinfections in COVID-19, and its different Bacterial types were extracted. Heterogeneity was determined using Cochran's Q test of heterogeneity, and the I 2 index was used to quantify heterogeneity. Following the Higgins classification approach, I 2 values above 0.7 were considered as high heterogeneity. The pooled prevalence with 95% confidence interval (CI) was calculated using the "metaprop" command, and to estimate the pooled prevalence, we used the random-effects model. It should be noted the "Freeman-Tukey double-arcsine transformation" method used for estimating 95% CI to keeps the value between 0 and 100%. The meta-regression analysis was used to examine age, WHO region and sample size as factors affecting heterogeneity among studies. The "metabias" command was used to check the publication bias. If there was any publication bias, the prevalence rate was adjusted with the "meta-trim" command using the trim-and-fill method. In all analyses, a significance level of 0.05 was considered. 

The prevalence of bacterial coinfections in all included studies was listed in Table 1 in COVID-19 patient based on type of the bacteria, different regional places (AMRO: Regional Office of Americas; EURO: Regional Office for Europe; SEARO: Regional Office for South-East Asia; EMRO: Regional Office for the Eastern Mediterranean; WPRO; Regional Office for the Western Pacific) and type of the study. The diamond mark J o u r n a l P r e -p r o o f illustrates the pooled prevalence and the length of the diamond indicates the 95% CI. N is the number of the study in the analysis. The prevalence for EMRO (N=1) was 100 % (95% CI: 82.35 to 100.00). respectively. More detail was showed in Figure 3 . Table 2 presents the results of the heterogeneity. According to Cochran's Q test of heterogeneity, there was significant heterogeneity among studies (p<0.001). The I 2 index for total bacterial coinfections was 99%. According to meta-regression results, the age (Coefficient: -0.205; p: 

Based on the results of Begg's test, a significant publication bias was observed for total bacterial coinfections (Z-score: 4.11; p<0.001). Therefore, the fill and trim adjusted pooled prevalence of bacterial coinfections (23.55%; 95% CI: 18.38 to 28.73) was generated, which was not J o u r n a l P r e -p r o o f individuals. Critically ill patients demonstrated 8.1% of coinfection which is slightly more compare to 5.9% in hospitalized individuals [59] . Another meta-analysis article showed that 7%

of patients was infected with bacterial pathogens [60] . Bacterial co infection in the meta-analysis study was observed in 3.5% of patients. Bacterial secondary infection was identified in 14.3% of patients. This meta-analysis indicated that the most common bacterial co infection amongst covid-19 patients were Mycoplasma pneumonia, Pseudomonas aeruginosa and Haemophilus influenzae. This study also mentioned 3% of the patients were co infected with viruses. Median ages ranges from 42 to 63 years in most of the studies included in this meta-analysis [60] .

The overall prevalence of bacterial coinfection in COVID-19 patients was 6.9%. Nearly all of the studies indicated that the patients received some kind of antibiotics [59] . Bacterial coinfection plays an undeniable role in increasing morbidity and mortality rate in viral pandemics such as influenza [61] . Bacterial coinfection among patients infected with influenza virus has been reported up to 30% [1] .

One of the important aspect of determining the incidence and prevalence of bacterial coinfection is related to antibiotic prescription for COVID-19 patients [25] . Although the use of antibiotic in coronavirus patients is rapidly growing but the effectiveness of them are under questioning. A number of studies have questioned the amount of prescribing antibiotic for the patients and have opinioned that this will cause us another great challenge which is antibiotic resistance but on the other hand utilization of antibiotic in the pandemic situation is inevitable for different reasons the difficulties of excluding bacterial coinfection and the possibility of secondary infection in patients [62] .

Over 70% of covid-19 patients received some kind of antibiotics with a focus on broad-spectrum agents such as fluoroquinolones and third-generation cephalosporins [59] . Bacterial coinfection also reported in pervious pandemics. During the 2009 influenza (H1N1) pandemic Patients in intensive care units showed up to 30% of bacterial coinfection. The most commonly identified pathogens were S.aureus and S.pneumoniae [1, 63] .

In contrast in the recent COVID-19 pandemic it becomes more and more clear that Gramnegative and atypical bacteria are the most isolated bacteria from SARS-COV-2 patients. A meta-analysis study showed that the most common organisms reported by the studies were

Mycoplasma species, Haemophilus influenzae and Pseudomonas aeruginosa [59] .

Gram-negative microorganisms were also reported the most frequent cause of lower respiratory tract infection (LRTI). Pseudomonas aeruginosa was the most common isolated bacteria among patients with ventilator-associated pneumonia (VAP) (38%) and tracheobronchitis (33%) ( [64] .

Another systematic review and meta-analysis showed that the commonest bacteria were

Mycoplasma pneumonia, Pseudomonas aeruginosa and Haemophilus influenzae [60] .

But there are controversial data about SARS COV-2 co infection with these bacteria. Langford

and their colleague showed that these bacterial pathogens are not common amongst people with COVID-19 yet another meta-analysis study reported the rate of S. aureus/COVID-19 coinfection was 25.6% and the proportion of COVID-19/ MRSA S. aureus was 53.9%, which has been collected from five different studies [59, 65] .

Johns Hopkins scientists in a multicenter study found only 1.2% of the patients had bacterial coinfection which is less frequent than other studies. The researchers suggested that their vary data may be related to inclusion and exclusion criteria used by them [66] . They also mentioned their sampling time could be an effective factor compare to other studies. Their study was J o u r n a l P r e -p r o o f conducted in spring whereas other studies were implemented during winter in Europe and China.

They also indicated variation in vaccination background of sample population against pneumococcal infection and this may also affected the coinfection prevalence [67] .

Although it is not the main focus of our study it worth to mention that the co-infection of other microorganism such as viruses and fungal with SARS-COV2. The rate of fungal co-infection with SARS-COV2 has been reported diversely.

A systematic review and meta-analysis conducted by Jackson S. Musuuza found the prevalence of fungal co-infections, 4% and fungal superinfections, 8% among covid-19 patients [68] . In contrast another study repoterd that the overall pooled proportion of patients with co-infection was only 0.12 [69] . and cardiovascular comorbidities has a higher chance to be infected with bacterial infection. In addition these patients had worsen illness situation and showed multiple set of system failure [29, 67] .

COVID-19 patient's laboratory results have several clinical risk factor related with co infection.

A case-control study reported that C reactive protein (C RP) and Median neutrophil to lymphocyte ratio (NLR) were significantly higher in Case compared to controls. Although there was not any statistical significance in procalcitonin levels in COVID 19 patients with bacterial infection compare to people without bacterial infection [69] . Whereas Shengyang and his colleague found that COVID-19 patients with bacterial coinfection had substantially increase in J o u r n a l P r e -p r o o f their procalcitonin. This article also confirms the increase in C reactive protein (C-RP) in the patients [67] .

Similar to other studies, our research had some limitations. 1: we would like to perform the gender-specific estimation, but it was not possible due to insufficient data in the primary studies;

2: we estimated the pooled prevalence based on WHO regional office and tendency to examine the spatial analysis in different geographical regions based on available methods [70] [71] [72] but since the infrequent studies number, this estimation will not be robust. Also SEARO subgroup,

we have only 2 studies and this maybe cause un-robust estimates. Doing a comprehensive search and estimate the pooled prevalence based on different bacteria subtype was the current study's strengths.

Because of the proven track of bacterial coinfection in increasing morbidity and mortality rate in pervious viral outbreaks and pandemics proving information's about the incidence and prevalence rate of the them are crucial for health administrators and clinicians but the contrary data proves that various factor affect the final output of the studies and setting clinical guidelines or prescribing medication based on the results of different research's should be done carefully and considering all of the factor which yield effect on the final results. Considering the multiple complication and adverse effect of extensive use of antibiotics in COVID-19 patients but it seems there is no other option except the applying them but it needs to be done carefully

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

J o u r n a l P r e -p r o o f

Coronavirus Disease-19

SARS-CoV-2 infection [text word] OR SARS-CoV-2 infection

Mixed Infection [text word] OR Mixed Infection

Polymicrobial Infection [text word] OR Polymicrobial Infection

Bacterial Coinfection [text word] OR Bacterial Coinfection

Google Scholar was used to accessing gray literature. Also, a Bacteriology expert was consulted References

Critical illness from 2009 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States

Cold Spring Harbor perspectives in medicine

Critically ill patients with 2009 influenza A (H1N1) infection in Canada

Bacterial and viral infections associated with influenza. Influenza and other respiratory viruses

How do viral infections predispose patients to bacterial infections? Current opinion in infectious diseases

Clinical management of COVID-19: interim guidance

World Health Organization

SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO molecular medicine

How covid-19 is accelerating the threat of antimicrobial resistance

Collateral damage of the COVID-19

Exacerbation of antimicrobial resistance and disruptions to antimicrobial stewardship programmes?

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Global and regional prevalence of age-related cataract: a comprehensive systematic review and metaanalysis

Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies

Global and regional prevalence of strabismus: a comprehensive systematic review and metaanalysis

Global and regional estimates of prevalence of amblyopia: A systematic review and meta-analysis

COVID-19 associated central nervous system manifestations, mental and neurological symptoms: a systematic review and meta-analysis

Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia

Primary respiratory bacterial coinfections in patients with COVID-19. The American journal of tropical medicine and hygiene

Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster

Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU

Differentiating influenza from COVID-19 in patients presenting with suspected sepsis

Secondary bacterial infections in critical ill patients of COVID-19. Open forum infectious diseases

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19

and Mycoplasma pneumoniae in the USA

Bacterial infections and patterns of antibiotic use in patients with COVID-19

A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis

Coinfections with SARS-CoV-2 and other respiratory pathogens

Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the influence of intensive preventive measures in Japan

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK

Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Frontiers in medicine

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

CoV-2 and other respiratory pathogens in patients with COVID-19 in Guangzhou

Effect of a previous history of antiretroviral treatment on the clinical picture of patients with co-infection of SARS-CoV-2 and HIV: A preliminary study

Clinical characteristics and coinfections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study

Coinfection of SARS-CoV-2 and other respiratory pathogens. Infection and Drug Resistance

Respiratory Microbial Co-infection With SARS-CoV-2

COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge

Increased risk of acquisition of New Delhi metallo-beta-lactamase-producing carbapenemresistant Enterobacterales (NDM-CRE) among a cohort of COVID-19 patients in a teaching hospital in Tuscany

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship

Tuberculosis and COVID-19: An overlapping situation during pandemic

Bacteremia and blood culture utilization during COVID-19 surge in New York City

Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU

SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections

Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Traditional Herbal Remedies with a Multifunctional Therapeutic Approach as an Implication in COVID-19 Associated Co-Infections

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Coinfection and other clinical characteristics of COVID-19 in children

Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. The Journal of Infection

Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19

Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae. The Journal of infection

Risks and features of secondary infections in severe and critical ill COVID-19 patients

Co-infection with respiratory pathogens among COVID-2019 cases

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Co-infections in people with COVID-19: a systematic review and meta-analysis

Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses

New threatening of SARS-CoV-2 co-infection and strategies to fight the current pandemic

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

Random effects meta-analysis of COVID-19/S. aureus partnership in co-infection. GMS hygiene and infection control

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open forum infectious diseases

Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis

Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case control study

Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013

Spatio-temporal analysis of cutaneous leishmaniasis using geographic information system among Iranian Army Units and its comparison with the general population of Iran during 2005-2014

Spatiotemporal analysis of brucellosis incidence in Iran from 2011 to 2014 using GIS

Supplement 1: detail of bacterial coinfections in included studied based on different subtypes ID Author Gastrointestinal Bacteria Respiratory Bacteria

Enterococcus faecium: (0.005%) NR

Streptococcus Aureus: (55.4%)

Moraxella catarrhalis: (6.25 %)

8%); Pseudomonas aeruginosa